查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1570809

老年痴呆症症药物市场：按药物类别、类型、分布划分 - 全球预测 2025-2030

Alzheimer's Therapeutics Market by Drug Class (Cholinesterase Inhibitors, NMDA [N-methyl-D-aspartate] Receptor Antagonist), Type (Medication, NMDA Receptor Antagonist), Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

老年痴呆症症药物市场2023年估值为61.4亿美元，预计2024年将达到66.6亿美元，复合年增长率为8.63%，预计到2030年将达到109.6亿美元。

老年痴呆症症的治疗范围包括所有旨在预防、减缓或治疗阿兹海默症（一种进行性神经退化性疾病）的产品和化合物。这包括旨在针对阿兹海默症的潜在机制的各种药物、生技药品和生活方式干预措施。世界的老化以及阿兹海默症造成的沉重心理和经济负担强调了开发有效治疗方法的必要性。阿兹海默症症药物主要用于医院、诊所和专门护理机构等医疗环境，重点是改善患者的生活品质和减轻看护者的负担。最终用途范围广泛，包括製药公司、研究实体、医疗保健提供者和患者本身。

主要市场统计
基准年[2023] 61.4亿美元
预测年份 [2024] 66.6亿美元
预测年份 [2030] 109.6亿美元
复合年增长率（%） 8.63%

该市场的关键成长要素包括阿兹海默症的日益普及、生物技术的进步、合作研究和开发的激增以及政府资助神经科学研究的倡议。机会在于开发疾病修正治疗、透过生物标记进行的个人化医疗以及用于早期诊断和监测的创新数位工具。鼓励相关人员利用官民合作关係关係并在药物发现中利用人工智慧来增强其竞争地位。然而，新兴市场面临药物开发成本高、核准流程长、后期临床试验结果令人失望以及对疾病病理学了解有限等限制。

挑战包括监管障碍、报销问题以及阿兹海默症，这些都使药物开发变得复杂。创新和研究应着重于新的治疗方法，例如基因治疗药物，探索肠脑轴的影响，并利用多组学体学进行生物标记识别。市场仍然竞争激烈且研究密集型，需要不断创新才能满足监管标准和消费者期望。公司应优先考虑适应性策略，例如动态临床试验模型和与高科技公司的合作伙伴关係，以促进强劲的市场成长。对于希望在老年痴呆症症药物领域取得成功的公司来说，积极主动、敏捷地应对这些多样化的挑战至关重要。

市场动态：揭示快速发展的老年痴呆症药物市场的关键市场洞察

供需的动态交互作用正在改变老年痴呆症症药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，以及消费行为及其对製造成本的影响及其对采购趋势的影响。

波特五力：驾驭老年痴呆症症药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解老年痴呆症症药物市场的外部影响

外部宏观环境因素在塑造老年痴呆症症药物市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解老年痴呆症治疗药物市场的竞争状况

对老年痴呆症症药物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 在老年痴呆症症治疗市场的定位矩阵供应商绩效评估

FPNV定位矩阵是评估老年痴呆症治疗市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，规划老年痴呆症症药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，老年痴呆症症药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

该报告提供了涵盖关键焦点细分市场的全面市场分析。

1. 市场渗透率：对当前市场环境的详细回顾。

2. 市场开拓：辨识新兴市场的成长机会，评估现有产业的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：全面分析竞争格局，检视市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 阿兹海默症在人群中的发生率不断上升
      • 扩大管道药物开发和供应
      • 改善医疗设施和技术以早期发现阿兹海默症
    • 抑制因素
      • 阿兹海默症的资本密集型治疗
    • 机会
      • 结合云端基础的认知系统和人工智慧的密集研发
      • 新生物标誌物和再生医学的开发
    • 任务
      • 严格的医药品认证过程
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章老年痴呆症药物市场：依药物类别

  • 介绍
  • 胆碱酯酶抑制剂
  • NMDA [N-甲基-D-天门冬胺酸]受体拮抗剂

第七章老年痴呆症药物市场：按类型

  • 介绍
  • 药物治疗
    • 胆碱酯酶抑制剂
    • 多奈哌齐
    • Galantamine
    • Rivastigmine
  • NMDA受体拮抗剂

第八章老年痴呆症症药物市场：依分布

  • 介绍
  • 网路药房
  • 零售药房

第九章 美洲老年痴呆症症药物市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太老年痴呆症症药物市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲老年痴呆症药物市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 老年痴呆症治疗的下一阶段使用阿图他汀 ACD680
    • Arzecure 选择 CD 进行阿兹海默症药物阿图他汀 ACD680 的下一阶段开发
  • 战略分析和建议
Product Code: MRR-A77F2EE7AADB

The Alzheimer's Therapeutics Market was valued at USD 6.14 billion in 2023, expected to reach USD 6.66 billion in 2024, and is projected to grow at a CAGR of 8.63%, to USD 10.96 billion by 2030.

The scope of Alzheimer's therapeutics encompasses all products and compounds aimed at preventing, slowing, or treating Alzheimer's disease, a progressive neurodegenerative disorder. This includes a range of pharmaceuticals, biologics, and lifestyle interventions designed to target the underlying mechanisms of Alzheimer's. The necessity of developing effective treatments is underscored by the aging global population and the high emotional and economic burden of Alzheimer's. Its application is primarily in healthcare settings-hospitals, clinics, and specialized care facilities-focusing on improving patient quality of life and reducing caregiver strain. The end-use scope is vast, encompassing pharmaceutical companies, research institutions, healthcare providers, and patients themselves.

KEY MARKET STATISTICS
Base Year [2023] USD 6.14 billion
Estimated Year [2024] USD 6.66 billion
Forecast Year [2030] USD 10.96 billion
CAGR (%) 8.63%

Key growth factors in this market include increasing prevalence rates of Alzheimer's, advancements in biotechnology, a surge in collaborative R&D efforts, and government initiatives funding neuroscience research. Opportunities lie in the development of disease-modifying therapies, personalized medicine through biomarkers, and breakthrough digital tools for early diagnosis and monitoring. It is recommended that stakeholders tap into public-private partnerships and leverage artificial intelligence for drug discovery to enhance their competitive positioning. However, the market faces limitations such as high drug development costs, lengthy approval processes, disappointing late-stage clinical trial results, and limited understanding of disease pathology.

Challenging factors include regulatory hurdles, reimbursement issues, and the complex multi-faceted etiology of Alzheimer's that complicates treatment development. Innovation and research should focus on novel therapeutic modalities like gene therapy, exploring the gut-brain axis influence, and leveraging multi-omics approaches for biomarker identification. The market's nature remains highly competitive and research-intensive, with a need for continual innovation to meet regulatory standards and consumer expectations. Firms should prioritize adaptive strategies, such as dynamic clinical trial models and partnerships with tech companies, to foster robust market growth. Addressing these diverse challenges through proactivity and agility will be crucial for businesses aiming to succeed in the Alzheimer's therapeutics landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Alzheimer's Therapeutics Market

The Alzheimer's Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidences of Alzheimer's among population
    • Growing development and availability of pipeline drugs
    • Improved healthcare facilities and technologies for early detection of Alzheimer's
  • Market Restraints
    • Capital intensive treatment for Alzheimer's
  • Market Opportunities
    • Intense research and development with inclusion of cloud-based cognitive systems and artificial intelligence
    • Development of novel biomarkers and emerging regenerative therapies
  • Market Challenges
    • Stringent drug approval processes

Porter's Five Forces: A Strategic Tool for Navigating the Alzheimer's Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Alzheimer's Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Alzheimer's Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Alzheimer's Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Alzheimer's Therapeutics Market

A detailed market share analysis in the Alzheimer's Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Alzheimer's Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Alzheimer's Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Alzheimer's Therapeutics Market

A strategic analysis of the Alzheimer's Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Alzheimer's Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AC Immune SA, Acadia Pharmaceuticals Inc., Alnylam Pharmaceuticals, Inc., AlzeCure Pharma AB, Alzheon, Inc., AstraZeneca PLC, Biogen Inc., Cassava Sciences, Inc., Cognition Therapeutics, Inc., Corium, Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Grifols S.A., H. Lundbeck A/S, Luye Pharma Group Ltd., Merz Pharma GmbH & Co. KGaA, NeuroVision Imaging, Inc., Novartis AG, Oryzon Genomics, S.A., Pfizer, Inc., Siemens Healthcare GmbH, Synaptogenix, Inc., TauRx Pharmaceuticals Ltd., and VTV Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Alzheimer's Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Cholinesterase Inhibitors and NMDA [N-methyl-D-aspartate] Receptor Antagonist.
  • Based on Type, market is studied across Medication and NMDA Receptor Antagonist. The Medication is further studied across Cholinesterase inhibitors, Donepezil, Galantamine, and Rivastigmine.
  • Based on Distribution, market is studied across Online Pharmacies and Retail Pharmacies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidences of Alzheimer's among population
      • 5.1.1.2. Growing development and availability of pipeline drugs
      • 5.1.1.3. Improved healthcare facilities and technologies for early detection of Alzheimer's
    • 5.1.2. Restraints
      • 5.1.2.1. Capital intensive treatment for Alzheimer's
    • 5.1.3. Opportunities
      • 5.1.3.1. Intense research and development with inclusion of cloud-based cognitive systems and artificial intelligence
      • 5.1.3.2. Development of novel biomarkers and emerging regenerative therapies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent drug approval processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Alzheimer's Therapeutics Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Cholinesterase Inhibitors
  • 6.3. NMDA [N-methyl-D-aspartate] Receptor Antagonist

7. Alzheimer's Therapeutics Market, by Type

  • 7.1. Introduction
  • 7.2. Medication
    • 7.2.1. Cholinesterase inhibitors
    • 7.2.2. Donepezil
    • 7.2.3. Galantamine
    • 7.2.4. Rivastigmine
  • 7.3. NMDA Receptor Antagonist

8. Alzheimer's Therapeutics Market, by Distribution

  • 8.1. Introduction
  • 8.2. Online Pharmacies
  • 8.3. Retail Pharmacies

9. Americas Alzheimer's Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Alzheimer's Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Alzheimer's Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. The Next Phase of Alzheimer's Therapeutics with Alzstatin ACD680
    • 12.3.2. Alzecure Selects CD and Enters Next Development Phase with Alzstatin ACD680 against Alzheimer's
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AC Immune SA
  • 3. Acadia Pharmaceuticals Inc.
  • 4. Alnylam Pharmaceuticals, Inc.
  • 5. AlzeCure Pharma AB
  • 6. Alzheon, Inc.
  • 7. AstraZeneca PLC
  • 8. Biogen Inc.
  • 9. Cassava Sciences, Inc.
  • 10. Cognition Therapeutics, Inc.
  • 11. Corium, Inc.
  • 12. Eisai Co., Ltd.
  • 13. Eli Lilly and Company
  • 14. F. Hoffmann-La Roche Ltd.
  • 15. Grifols S.A.
  • 16. H. Lundbeck A/S
  • 17. Luye Pharma Group Ltd.
  • 18. Merz Pharma GmbH & Co. KGaA
  • 19. NeuroVision Imaging, Inc.
  • 20. Novartis AG
  • 21. Oryzon Genomics, S.A.
  • 22. Pfizer, Inc.
  • 23. Siemens Healthcare GmbH
  • 24. Synaptogenix, Inc.
  • 25. TauRx Pharmaceuticals Ltd.
  • 26. VTV Therapeutics

LIST OF FIGURES

  • FIGURE 1. ALZHEIMER'S THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ALZHEIMER'S THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ALZHEIMER'S THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ALZHEIMER'S THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ALZHEIMER'S THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ALZHEIMER'S THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY NMDA [N-METHYL-D-ASPARTATE] RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY NMDA RECEPTOR ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM ALZHEIMER'S THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. ALZHEIMER'S THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. ALZHEIMER'S THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023